A clinical trial by Prof. Jean-Pierre Pelletier has been published in Annals of the Rheumatic Diseases this week
The positive effect of this SYSADOA on cartilage and on subchondral bone has significant implications not only from a clinical but also from a pharmacoeconomic point of view.
This clinical trial confirms the disease modifying properties of chondroitin sulphate, previously evidenced by X-rays, and contradicts the conclusions of a recent meta-analysis published in the British Medical Journal in 2010.
MONTREAL, March 28 /CNW/ - A group of Canadian researchers led by Prof. Jean-Pierre Pelletier, Head of the Osteoarthritis Research Unit, at the University of Montreal Hospital Research Centre, published a clinical trial, in which they confirm, for the first time using quantitative Magnetic Resonance Imaging (qMRI), the disease modifying effects of chondroitin sulphate, a symptomatic slow acting drug for osteoarthritis (SYSADOA).
